BioStock: Aptahem gives update on operations and rights issue

Aptahem is making strides in the field of sepsis treatment with its drug candidate Apta-1. Recently, the company announced the completion of a fourth cohort in the ongoing phase I clinical study. Aptahem has also attended key partnering conferences to showcase its potential sepsis treatment. To learn more about this, and the share issue of 28 MSEK between 14 June – 28 June 2023, BioStock talked to CEO Mikael Lindstam.

Read the interview with Aptahem's CEO Mikael Lindstam at biostock.se:

https://www.biostock.se/en/2023/06/aptahem-gives-update-on-operations-and-rights-issue/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/